PMS-PROPAFENONE 300 MG
PROPAFENONE HYDROCHLORIDE : 300 MG · DIN 02294575 · PHARMASCIENCE INC
Health Canada status: CANCELLED POST MARKET
What is PMS-PROPAFENONE?
PMS-PROPAFENONE 300 MG contains PROPAFENONE HYDROCHLORIDE : 300 MG. It is listed in the Health Canada Drug Product Database under DIN 02294575, held by PHARMASCIENCE INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 04-Jul-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PMS-PROPAFENONE used for?
Treatment of documented life-threatening ventricular arrhythmias (e.g., sustained VT) and symptomatic ventricular arrhythmias of sufficient severity.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02294575 |
|---|---|
| Brand name | PMS-PROPAFENONE |
| Generic / active ingredient | PROPAFENONE HYDROCHLORIDE : 300 MG |
| Manufacturer | PHARMASCIENCE INC |
| Strength | 300 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C01BC03 PROPAFENONE |
| AHFS class | 24:04.04.12 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 04-Jul-2025 |
| Original market date | 2008-02-22 00:00:00 |
How is it administered?
Initiate in hospital for sustained VT. Dosage must be individualized. Common doses range from 450 mg to 900 mg per day in divided doses. Reduce dose in hepatic impairment.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (Table of Contents lists page 20, but text ends earlier).
How is it supplied?
Not explicitly detailed in provided text (mentions 150 mg and 300 mg strengths).
Contraindications
Hypersensitivity; Brugada Syndrome; MI within 3 months; severe/uncontrolled CHF; cardiogenic shock; conduction disorders without pacemaker; bradycardia; hypotension; bronchospastic disorders; ritonavir.
Warnings and precautions
Proarrhythmic effects; may cause/worsen CHF; slows cardiac conduction (PR/QRS prolongation); agranulocytosis risk; may unmask Brugada Syndrome; negative inotropic effects.
What can be used instead?
Other Canadian products sharing ATC code C01BC03 PROPAFENONE. 6 of 19 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-PROPAFENONE | 150 MG | TABLET | APOTEX INC | MARKETED | DIN 02243324 |
| APO-PROPAFENONE | 300 MG | TABLET | APOTEX INC | MARKETED | DIN 02243325 |
| MYLAN-PROPAFENONE | 150 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02457172 |
| MYLAN-PROPAFENONE | 300 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02457164 |
| RYTHMOL | 150 MG | TABLET | BGP PHARMA ULC | MARKETED | DIN 00603708 |
| RYTHMOL | 300 MG | TABLET | BGP PHARMA ULC | MARKETED | DIN 00603716 |
| MYL-PROPAFENONE | 150 MG | TABLET | MYLAN PHARMACEUTICALS ULC | CANCELLED POST MARKET | DIN 02245372 |
| MYL-PROPAFENONE | 300 MG | TABLET | MYLAN PHARMACEUTICALS ULC | CANCELLED POST MARKET | DIN 02245373 |
| NU-PROPAFENONE | 150 MG | TABLET | NU-PHARM INC | CANCELLED (UNRETURNED ANNUAL) | DIN 02249480 |
| PMS-PROPAFENONE | 150 MG | TABLET | PHARMASCIENCE INC | CANCELLED POST MARKET | DIN 02294559 |
Who else supplies PROPAFENONE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. PROPAFENONE appears in 49 registered pack listings across 8 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.